There has been an increase in the incidence of nontuberculous mycobacterial infections after breast augmentation and other procedures over the past several years.1–5 We present a case of bilateral mycobacterial infection after transareolar subpectoral breast augmentation with occurrence of chronic draining fistulas at the incision sites after implant removal so as to alert surgeons to this unexpected complication.
An otherwise healthy 44-year-old woman underwent transareolar subpectoral breast augmentation with 500-cc saline implants. Four weeks later, she developed slight swelling of her right breast, with no fever, erythema, pain, or tenderness. The patient was placed on oral linezolid (600 mg twice daily). Ten days later, an area of erythema developed on the inferomedial aspect of the right breast, prompting implant removal through an inframammary crease incision. Approximately 200 ml of turbid fluid was drained, the Gram stain of which showed a white blood cell count of 4+ and no bacteria. Results of routine cultures were negative. Although closed tube drainage was used, the patient developed serous drainage through the inframammary incision site. The amount of drainage diminished slowly and the fistula closed spontaneously within 3 months.
Two weeks after removal of the right implant, the patient became febrile and developed pain and erythema over the inferolateral aspect of the left breast. These symptoms prompted immediate removal of the left breast implant, again through an inframammary crease incision. Approximately 100 ml of turbid material was removed and submitted for Gram stain and cultures. As it was noted during this—and the previous, right-sided—explantation that the tissues surrounding the implant appeared normal without detectable capsule formation, no attempt was made to excise any granulation tissue or perform capsulectomy. Closed tube drainage was again performed. Gram stain showed a white blood cell count of 2+ with no organisms. The final bacteriology report indicated Mycobacterium abscessus. The patient showed improvement of her signs and symptoms within 2 to 3 days after explantation. A new antibiotic regimen was initiated by the infectious disease consultant that was continued for 6 months. Approximately 1 week after implant removal, the patient developed a fistula tract similar to the one on the right breast involving the left inframammary crease incision. This fistula closed spontaneously within 3 weeks.
Because of the recent rise in outbreaks of mycobacterial infections1–5 and because clinical diagnosis of mycobacterial infection after breast augmentation may be delayed,5 we strongly recommend laboratory staining for acid-fast bacilli in addition to routine Gram stain and culture studies in all patients who undergo implant removal. A standard Gram stain frequently fails to identify acid-fast bacilli. Furthermore, we bring attention to the occurrence of a chronic fistula as a potential complication of atypical mycobacterial breast implant infection. The treatment goal should involve controlling the infection medically, without necessarily removing the periprosthetic granulation tissue or the capsule at the time of explantation or when a fistula has formed.
David J. Jackowe, M.D.
Daniel Murariu, M.D.
Department of Surgery
Natalie N. Parsa, M.D.
Department of Family Practice
F. Don Parsa, M.D.
Department of Surgery
John A. Burns School of Medicine
University of Hawaii at Manoa
1. Meyers H, Brown-Elliott BA, Moore D, et al. An outbreak of Mycobacterium chelonae
infection following liposuction. Clin Infect Dis.
2. Haiavy J, Tobin H. Mycobacterium fortuitum
infection in prosthetic breast implants. Plast Reconstr Surg.
3. Falkinham JO III. The changing pattern of nontuberculous mycobacterial disease. Can J Infect Dis.
4. Macadam SA, Mehling BM, Fanning A, et al. Nontuberculous mycobacterial breast implant infections. Plast Reconstr Surg.
5. Brickman M, Parsa AA, Parsa FD. Mycobacterium cheloneae
infection after breast augmentation. Aesthetic Plast Surg.
Viewpoints, pertaining to issues of general interest, are welcome, even if they are not related to items previously published. Viewpoints may present unique techniques, brief technology updates, technical notes, and so on. Viewpoints will be published on a space-available basis because they are typically less timesensitive than Letters and other types of articles. Please note the following criteria:
Authors will be listed in the order in which they appear in the submission. Viewpoints should be submitted electronically via PRS' enkwell, at www.editorialmanager.com/prs/. We strongly encourage authors to submit figures in color.
We reserve the right to edit Viewpoints to meet requirements of space and format. Any financial interests relevant to the content must be disclosed. Submission of a Viewpoint constitutes permission for the American Society of Plastic Surgeons and its licensees and assignees to publish it in the Journal and in any other form or medium.
The views, opinions, and conclusions expressed in the Viewpoints represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.